Journal

Current problems in cancer
ISSN: 1535-6345
Titre abrégé: Curr Probl Cancer
Pays: United States
ID NLM: 7702986

Informations de publication

Date de publication:
10 2021
Historique:
received: 18 08 2021
accepted: 02 09 2021
pubmed: 29 10 2021
medline: 5 2 2022
entrez: 28 10 2021
Statut: ppublish

Résumé

Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy. In a first-in-human dose escalation trial of bone targeted Radium 223 dichloride alpha-particle therapy in 18 patients with advanced osteosarcoma only 1 patient responded based on conventional Response Evaluation Criteria in Solid Tumors (RECIST). Na

Identifiants

pubmed: 34706830
pii: S0147-0272(21)00114-8
doi: 10.1016/j.currproblcancer.2021.100797
pii:
doi:

Substances chimiques

Fluorine Radioisotopes 0
Radioisotopes 0
Sodium Fluoride 8ZYQ1474W7
Fluorine-18 GZ5I74KB8G
radium Ra 223 dichloride RJ00KV3VTG
Radium W90AYD6R3Q

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100797

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Kalevi Kairemo (K)

Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland.

Jason Roszik (J)

Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jroszik@mdanderson.org.

Pete Anderson (P)

Pediatric Hematology/Oncology/BMT, Cleveland Clinic, Cleveland, OH, USA.

Gregory Ravizzini (G)

Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Arvind Rao (A)

Department of Computational Medicine & Bioinformatics & Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

Homer A Macapinlac (HA)

Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Vivek Subbiah (V)

Department of Investigational Cancer Therapeutics (A Phase 1 Clinical trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH